CMTA has received a $154,000 American Camp Association Character at Camp Implementation Grant to launch the Footprint Fellowship: Bringing Camp Magic Home. The two-year initiative extends the Camp Footprint experience beyond summer for 35 inaugural Fellows and positions the program as a national model for character-driven camp programming.
CMTA Invests $141,000 to Study Hearing and Balance to Develop Better Clinical Trial Outcome Measures in Charcot-Marie-Tooth Disease
CMTA is supporting a two-year research project examining hearing and balance signaling to strengthen outcome measures in future CMT clinical trials.
CMTA Appoints David Stark, MD, and Catherine Illingworth to Board of Directors, Expanding Clinical and Biotech Expertise
CMTA welcomes David Stark, MD, and Catherine Illingworth to its Board of Directors, strengthening clinical insight and gene therapy leadership within the CMT community.
CMTA Addresses the Critical Delivery Challenge Underlying CMT Treatment Development through Four Key Investments
CMTA announced $523,000 in funding for four research projects focused on solving one of the biggest challenges in CMT treatment development: delivering therapies to peripheral nerve cells. By investing in genome-editing transport, blood-nerve barrier crossing, Schwann cell targeting, and nanoparticle systems, CMTA is working to ensure treatments can reach the cells where they are needed.
CMTA Appoints Wendy Arnone as Board Chair
CMTA has appointed Wendy Arnone as board chair, succeeding Gilles Bouchard, who has led the board since 2016 and will continue serving as a board member. Arnone brings decades of executive healthcare leadership experience and a clinical background as a registered nurse, positioning her to guide CMTA’s continued investment in research and drug development for CMT.
CMTA Invests $100,000 in EverTree Bio to Support Cutting-Edge Therapeutic Research for CMT1A
CMTA announces a $100,000 investment in EverTree Bio to support continued development of an early-stage therapeutic program for CMT1A. The investment builds on early testing through the CMTA Preclinical Toolbox and reflects CMTA’s role in keeping strong CMT-focused research moving when it might otherwise stall.
Charcot-Marie-Tooth Association Appoints Catie Coman as Chief Marketing Officer
Coman brings more than 15 years of experience in patient advocacy and has worked with non-profit organizations serving people living with psoriatic disease, inflammatory arthritis, atopic dermatitis, type 1 diabetes, and other chronic diseases.
CMTA Invests $281,339 to Advance Treatments for CMT1A
The newly funded study will test whether molecules originally in development as cancer therapeutics can also be used to lower PMP22 and improve nerve health in a model of CMT1A.
CMTA-INC Alliance Announces 2025 Inherited Neuropathies Fellowship Recipient: Orthopedic Surgeon to Focus on Improving Outcomes for People with CMT
The CMTA–INC Alliance announced the 2025 Inherited Neuropathies Fellowship recipient, supporting clinical research focused on corrective foot and ankle care and surgical outcomes for people with CMT.
CMTA Invests $210K in Long-Read Sequencing to Accelerate CMT Gene Discovery
CMTA is investing $210,000 in long-read sequencing to uncover hidden gene mutations in undiagnosed CMT cases and improve access to diagnosis and future treatments.
